Literature DB >> 35501263

Immune checkpoint inhibitor-related thyroid dysfunction.

Shintaro Iwama1, Tomoko Kobayashi2, Yoshinori Yasuda2, Hiroshi Arima3.   

Abstract

Immune-related adverse events (irAEs) are caused by immune checkpoint inhibitors in several organs including the endocrine glands. Thyroid dysfunction (thyroid irAEs) is often observed among endocrine irAEs and is induced by blockade of programmed cell death 1 (PD-1), programmed death ligand 1, or PD-1 plus cytotoxic T-lymphocyte antigen 4. Endocrinologically, destructive thyroiditis or hypothyroidism is observed in most cases, whereas hyperthyroidism (Graves' disease) is rare. Most patients who develop destructive thyroiditis or hypothyroidism subsequently require thyroid hormone replacement therapy. Thyroid irAE development is associated with prolonged survival in patients with non-small cell lung carcinoma. The incidence of thyroid irAEs is higher in patients who are positive versus negative for anti-thyroid antibodies at baseline, suggesting that these antibodies can predict thyroid irAE development. Cytotoxic T cells, especially CD4 T cells, are reportedly involved in the development of destructive thyroiditis. In this review, we describe the clinical features, potential biomarkers, and mechanism of thyroid irAEs.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PD-1; PD-L1; hyperthyroidism; hypothyroidism; irAE; thyrotoxicosis

Mesh:

Substances:

Year:  2022        PMID: 35501263     DOI: 10.1016/j.beem.2022.101660

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  1 in total

Review 1.  Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.

Authors:  Xavier Thuru; Romain Magnez; Hassiba El-Bouazzati; Gérard Vergoten; Bruno Quesnel; Christian Bailly
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.